REFERENCES
- Remy B., Deby Dupont G., Lamy M. Red Blood Cell Substitutes: Fluorocarbon Emulsions and Haemoglobin Solutions. Br. Med. Bull. 1999; 55: 277–298
- Habler O., Kleen M., Messmer K. Artificial Oxygen Carriers. Alternatives to Homologous Blood Transfusion?. Zentralbl. Chir. 1999; 124: 260–270
- Spence R. K., Norcross E. D., Costabile J., McCoy S., Cernaianu A. C., Alexander J. B., Pello M. J., Atabek U., Camishion R. C. Perfluorocarbons as Blood Substitutes: The Early Years. Experience with Fluosol DA-20% in the 1980s. Art. Cells Blood Subst. Immob. Biotechnol. 1994; 22: 955–963
- Takahashi K., Wasaki Y., Hata J., Mukai K., Goto T. Spontaneous Transformation and Immortalization of Human Endothelial Cells. In Vitro 1990; 25: 265–274
- Ziegler-Heitbrock H. W.L., Thiel E., Fütterer A., Herzog V., Wirtz A., Riethmüller G. Establishment of a Human Cell Line (Mono Mac 6) with Characteristics of Mature Monocytes. Int. J. Cancer 1988; 41: 456–461
- Edwards C. M., Lowe K. C., Röhlke W., Geister U., Reuter P., Meinert H. Effects of a Novel Perfluorocarbon Emulsion on Neutrophil Chemiluminescence in Human Whole Blood In Vitro. Art. Cells Blood Subst. Immob. Biotech. 1997; 25: 255–260
- Keipert P. E. Use of Oxygent, a Perfluorochemical-Based Oxygen Carrier, as an Alternative to Intraoperative Blood Transfusion. Art. Cells Blood Subst. Immob. Biotechnol. 1995; 23: 381–394
- Kaufman R. J. The Results of a Phase I Clinical Trial of a 40% V/V Emulsion of HM (Oxyfluor). Art. Cells Blood Subst. Immobil. Biotechnol. 1994; 22: A112
- Ohyanagi H., Saitoh Y. Development and Clinical Application of Perfluorochemical Artificial Blood. Int. J. Art. Organs 1986; 9: 363–368
- Gould S. A., Rosen A. L., Sehgal L. R., Sehgal H. L., Langdale L. A., Krause L. M., Rice C. L., Chamberlin W. H., Moss G. S. Fluosol-DA as a Red-Cell Substitute in Acute Anemia. N. Engl. J. Med. 1986; 314: 1653–1656
- Wall T. C., Califf R. M., Blankenship J., Talley J. D., Tannerbaum M., Schwaiger M., Gacioch G., Cohen M. D., Sauz M., Leimberger J. D. Intravenous Fluosol in the Treatment of Acute Myocardial Infarction. Circulation 1994; 90: 114–126
- Jaffe C. C., Wohlgelernter D., Cabin H., Bowman L., Dechelbaum L., Remetz M., Cleman M. Preservation of Left Ventricular Ejection Fraction During Percutaneous Transluminal Coronoary Angioplasty by Distal Transcatheter Coronary Perfusion of Oxygenated Fluosol DA 20%. Am. Heart J. 1988; 6: 1156–1164
- Bajaj A. K., Cobb M. A., Virmani R., Gay J. C., Light R. T., Forman M. B. Limitation of Myocardial Reperfusion Injury by Intravenous Perfluorochemicals: Role of Neutrophil Activation. Circulation 1989; 79: 645–656
- Forman M. B., Pitarys C. J., II, Vildibill H. D., Lambert T. L., Ingram D. A., Virmani R., Murray J. J. Pharmacologic Perturbation of Neutrophils by Fluosol Results in a Sustained Reduction in Infarct Size in the Canine Model of Reperfusion. J. Am. Coll. Cardiol. 1992; 19: 205–216
- Ohyanagi H. Perfluorochemical Emulsions as Blood Substitutes: Clinical Data and New Applications. Artificial Red Cells, E. Tsuchida. John Wiley and Sons, Chicester 1995; 199–226